Ubs Group Ag Longboard Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Longboard Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 37,303 shares of LBPH stock, worth $2.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,303

Previous 30,141 23.76%

Holding current value

$2.24 Million

Previous $814,000 52.7%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$27.58 - $39.5 $197,527 - $282,899	7,162 Added 23.76%	37,303 $1.24 Million
Q2 2024 Aug 13, 2024	SELL	$17.0 - $27.03 $152,541 - $242,540	-8,973 Reduced 22.94%	30,141 $814,000
Q1 2024 May 13, 2024	BUY	$18.89 - $26.06 $451,017 - $622,208	23,876 Added 156.69%	39,114 $844,000
Q4 2023 Feb 09, 2024	BUY	$3.68 - $6.5 $25,583 - $45,188	6,952 Added 83.9%	15,238 $91,000
Q3 2023 Nov 09, 2023	SELL	$5.49 - $7.49 $4,243 - $5,789	-773 Reduced 8.53%	8,286 $46,000
Q2 2023 Aug 11, 2023	BUY	$4.19 - $10.05 $35,744 - $85,736	8,531 Added 1615.72%	9,059 $66,000
Q1 2023 May 12, 2023	SELL	$3.84 - $5.96 $1,701 - $2,640	-443 Reduced 45.62%	528 $2,000
Q4 2022 Feb 08, 2023	BUY	$2.95 - $5.5 $2,864 - $5,340	971 New	971 $3,000
Q2 2022 Aug 10, 2022	BUY	$2.96 - $5.38 $189 - $344	64 New	64 $0
Q4 2021 Feb 14, 2022	SELL	$4.75 - $9.45 $6,792 - $13,513	-1,430 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$8.65 - $11.36 $15,215 - $19,982	-1,759 Reduced 55.16%	1,430 $13,000
Q2 2021 Aug 13, 2021	BUY	$7.95 - $17.3 $20,614 - $44,858	2,593 Added 435.07%	3,189 $29,000
Q1 2021 May 12, 2021	BUY	$16.0 - $16.89 $9,536 - $10,066	596 New	596 $10,000

Others Institutions Holding LBPH

# of Institutions

125

Shares Held

34.9M

Call Options Held

28.9K

Put Options Held

13.9K

View Full List

About Longboard Pharmaceuticals, Inc.

Ticker LBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,586,000
Market Cap $815M
Description
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...

More about LBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account